Clinical trials: Metastasis to Liver
Hepatectomy, Liver Failure
Hepatectomy Risk Assessment With Functional Magnetic Resonance Imaging
Liver resection remains the only curative option for primary or metastatic liver cancer, but a more accurate prediction of post-hepatectomy liver failure (PHLF) is needed to further reduce morbidity and mortality and to extend…
- Conditions
- Hepatectomy, Liver Failure, Liver Cancer, Liver Metastases
- Trial name
- HEPARIM (NCT04705194)
- Testing
- Hepatectomy, PVE or ALPPS
- Where
- United Kingdom
- Volunteers
- 134 people
- Sponsor
- University of Leeds
Colorectal Adenocarcinoma Metastatic to the Liver
Study Comparing HAI Plus Chemotherapy and Chemotherapy Alone in Patients With Unresectable CRLM
To date no prospective trials have been completed that demonstrated whether HAI is an effective adjunct to systemic chemotherapy (target therapy) with respect to advantages in conversional resection rates and survival compared…
- Trial name
- NCT03125161
- Testing
- HAI, chemotherapy ± target therapy
- Where
- China
- Volunteers
- 150 people
- Sponsor
- Fudan University
Colorectal Neoplasms, Neoplasm Metastasis
Treatment of Colorectal Liver Metastases With Immunotherapy and Bevacizumab
Liver is the most common site of metastases from colorectal cancer. Neoadjuvant chemotherapy with targeted agents is usually recommended for borderline-resectable liver metastases that are technically difficult to resect for…
- Conditions
- Colorectal Neoplasms, Neoplasm Metastasis, Colonic Neoplasms, Rectal Neoplasms
- Trial name
- CLIMB (NCT03698461)
- Testing
- Atezolizumab, Bevacizumab, Oxaliplatin
- Where
- South Korea
- Volunteers
- 20 people
- Sponsor
- Asan Medical Center
Cancer, Lung, Perfusion Computed Tomography Target Lesion
DCE-CT of Thoracic Tumors as an Early Biomarker for Treatment Monitoring in Comparison With Morphologic Criteria
DCE-CT of thoracic tumors as an early biomarker for treatment monitoring in comparison with morphologic criteria. 1. Rationale of the clinical investigation For the evaluation of response to anti-tumoral therapy in thoracic…
- Conditions
- Cancer, Lung, Perfusion Computed Tomography Target Lesion, Cancer Liver, Metastatic Lung Cancer
- Trial name
- NCT04708483
- Testing
- Extra DCE-CT scan
- Where
- Belgium
- Volunteers
- 100 people
- Sponsor
- Hyperfusion
Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc)
Interventional AI-Human Collaboration for Liver Tumor Diagnosis
Recent advances in artificial intelligence (AI), particularly deep learning technology, have transformed medical imaging analysis.
- Conditions
- Hepatocellular Carcinoma (HCC), Intrahepatic Cholangiocarcinoma (Icc), Hepatic Metastasis, Hepatic Hemangioma
- Trial name
- NCT07153783
- Testing
- AI-human collaboration for CE-CTs diagnosis
- Where
- China
- Volunteers
- 10,333 people, healthy volunteers welcome
- Sponsor
- Shengjing Hospital
Intraocular Melanoma, Melanoma (Skin)
Hepatic Arterial Infusion With Melphalan Compared With Standard Therapy in Treating Patients With Unresectable Liver Metastases Due to Melanoma
RATIONALE: Drugs used in chemotherapy, such as melphalan, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Intraocular Melanoma, Melanoma (Skin), Metastatic Cancer
- Trial name
- NCT00324727
- Testing
- melphalan, regional chemotherapy, systemic chemotherapy
- Where
- 12 sites in United States
- Volunteers
- 93 people
- Sponsor
- Delcath Systems Inc.
Colorectal Cancer, Liver Metastases From Colorectal Cancer
Prospective Cohort Study on the Relationship Between Exosomal Peroxiredoxin 1 (PRDX1) and Postoperative Liver Metastasis
The occurrence of liver metastasis after curative surgery for resectable colorectal cancer is an important cause of death for patients.
- Conditions
- Colorectal Cancer, Liver Metastases From Colorectal Cancer, Pathology, Exosome
- Trial name
- NCT07177742
- Testing
- Observation
- Where
- China
- Volunteers
- 260 people
- Sponsor
- Mu-qing Yang
Colorectal Cancer, Resectable Liver Metastasis
Phase 3 Study of Surgery Combined With Neoadjuvant Chemotherapy(XELOX) in Colorectal Cancer With Resectable Liver Metastasis
This study aims to discuss the efficacy and safety of neoadjuvant chemotherapy with XELOX regimen (oxaliplatin plus capecitabine) .
- Trial name
- NCT00630045
- Testing
- neoadjuvant chemotherapy with oxaliplatin and capecitabine, resection of liver metastasis
- Where
- 2 sites in China
- Volunteers
- 392 people
- Sponsor
- Peking University People's Hospital
Pancreatic Cancer, Liver Metastases
CE-IOUS for Patients With Pancreatic Cancer Undergoing Surgery: A Prospective, Proof-of-concept Trial
BACKGROUND: Pancreatic Cancer (PC) is one of the leading cancer-related causes of death worldwide, with the majority of patients undergoing potentially curative surgery.
- Trial name
- NCT04683497
- Testing
- Contrast-enhanced Intraoperative Ultrasound
- Volunteers
- 50 people
- Sponsor
- University of Thessaly
Colorectal Cancer Liver Metastases
Preoperative Nivolumab Plus Bevacizumab Combined With Chemotherapy Before Surgery in Patients With pMMR/MSS Colorectal Cancer Liver Metastases
This prospective, single-arm study aims to investigate the safety and efficacy of Nivolumab plus bevacizumab and chemotherapy as neoadjuvant treatment in pMMR/MSS Colorectal cancer liver metastases patients
- Trial name
- NCT05588297
- Testing
- CapOx(Capecitabine+ Oxaliplatin), Bevacizumab, Nivolumab
- Volunteers
- 12 people
- Sponsor
- Shanghai Changzheng Hospital
Gastrointestinal Carcinoid Tumor, Islet Cell Tumor
Doxorubicin Beads in Treating Patients With Unresectable Liver Metastases From Neuroendocrine Tumors
RATIONALE: Drugs used in chemotherapy, such as doxorubicin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing.
- Conditions
- Gastrointestinal Carcinoid Tumor, Islet Cell Tumor, Metastatic Cancer
- Trial name
- NCT00730483
- Testing
- PVA microporous hydrospheres/doxorubicin hydrochloride
- Where
- United States
- Volunteers
- 13 people
- Sponsor
- Yale University
Colorectal Cancer, Liver Metastasis
Liver Transplantation and Colorectal Cancer
Colorectal liver metastases (CLM) are currently considered an absolute contraindication for liver transplantation (Lt) although Lt for other primary and secondary liver malignancies show excellent outcome in selected patients.
- Trial name
- NCT01479608
- Testing
- Liver transplantation and liver resection
- Where
- Norway
- Volunteers
- 25 people
- Sponsor
- Oslo University Hospital
Colorectal Neoplasms
Evaluation of Metabolic Activity of Liver Metastases by FDG-PET Scanning
The purpose of this study is to evaluate the effect of primary tumor resection on the metabolic activity of metastases in patients with a colorectal primary tumor and synchronous liver metastases by positron emission tomography…
- Trial name
- NCT00184782
- Testing
- FDG-PET
- Where
- Netherlands
- Volunteers
- 30 people
- Sponsor
- Radboud University Medical Center
Liver Diseases, Liver Cancer
CRISPR-Edited HLA Donor Liver Transplant to Reduce Rejection
This early-phase clinical trial will assess the use of ex vivo CRISPR-Cas9 genome editing on donor liver grafts to reduce immunogenicity before transplantation.
- Conditions
- Liver Diseases, Liver Cancer, Liver Cirrhosis, Liver Failure
- Trial name
- NCT07053488
- Testing
- Ex Vivo CRISPR-Cas9 Gene Editing of Donor Liver
- Where
- China
- Volunteers
- 90 people
- Sponsor
- AMERICAN ORGAN TRANSPLANT AND CANCER RESEARCH INSTITUTE LLC
Liver Neoplasms, Hepatobiliary Diseases
Outcomes After Liver and Biliary Resection at a High-Volume Center
The goal of this observational study is to evaluate clinical and oncologic outcomes in adult patients undergoing liver and/or biliary resection for benign and malignant diseases.
- Conditions
- Liver Neoplasms, Hepatobiliary Diseases, Cholangiocarcinoma, Hepatocellular Carcinoma
- Trial name
- BILIVER (NCT07556835)
- Where
- Italy
- Volunteers
- 1,000 people
- Sponsor
- Azienda USL Toscana Centro
Liver Metastasis, Liver Mass
Evaluation of Suspected Liver Pathology in Patients With Contraindications for Contrast Enhanced CT and/or MRI
Patients with renal failure or other reason for contraindication for contrast enhanced computed tomography (CECT) or contrast enhanced magnetic resonance imaging (CEMRI) with suspected liver pathology will be evaluated with…
- Trial name
- NCT02651090
- Testing
- Sonazoid
- Sponsor
- Northeastern Ohio Radiology Research and Education Fund
Metastatic Solid Tumor Cancer, Recurrent Head and Neck Cancer
Safety and Efficacy of Intra-Arterial and Intra-Tumoral Ad-p53 With Capecitabine (Xeloda) or Anti-PD-1 in Liver Metastases of Solid Tumors and Recurrent Head and Neck Squamous Cell Cancer
This is a Phase 1/2 study of the combination of Ad-p53 administered intra-arterially in combination with oral metronomic capecitabine or pembrolizumab in patients with unresectable, refractory liver metastases of colorectal…
- Trial name
- NCT02842125
- Testing
- Ad-P53, Xeloda, Keytruda
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- MultiVir, Inc.
Colorectal Neoplasms
Anti-OX40 Antibody (MEDI6469) in Patients With Metastatic Colorectal Cancer
This study will test the ability of an immune modulator, anti-OX40 (MEDI6469) to alter the immune cell environment within colorectal cancer metastases. The drug will be administered to patients before surgical treatment.
- Trial name
- NCT02559024
- Testing
- MEDI6469
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- Providence Health & Services
Colorectal Cancer Metastatic
Study of Intratumoral Ipilimumab and TLR4 Agonist GLA-SE in Combination With Systemic Nivolumab and Chemotherapy
To determine the maximum tolerated dose (MTD), the recommended phase 2 dose (RP2D) and the toxicity profile (NCI CTCAE v5.0 and immune related adverse events) of i.t.
- Trial name
- ISILI (NCT03982121)
- Testing
- FOLFOX regimen, Nivolumab, Ipilimumab
- Where
- France
- Sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
Uveal Melanoma, Liver Metastases
CAVATAK® and Ipilimumab in Uveal Melanoma Metastatic to the Liver (VLA-024 CLEVER)
This is an open-label Phase 1b clinical study of ipilimumab in combination with intravenous CVA21 in subjects who have uveal melanoma metastatic to liver.
- Trial name
- CLEVER (NCT03408587)
- Testing
- CVA21, Ipilimumab
- Where
- 3 sites in United States
- Volunteers
- 11 people
- Sponsor
- Viralytics
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.